Paulina Hill

Dr. Paulina Hill serves as a Partner at Sanofi Ventures. Dr. Hill serves as Board Member at IFM Therapeutics, NextPoint & Normunity. She served as Board Member at Avilar Therapeutics. She served as Board Observer at Arrakis Therapeutics. She served as the Principal, of Investments at Omega Fund. She served as Board Observer at Scorpion Therapeutics. She served as Board Member at Kindex. She previously served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM), Lyra Pharmaceuticals, Faraday Pharmaceuticals, Arsenal Medical, and CAMP4 Therapeutics. Prior to joining Sanofi, she was a Principal on the investment team at Omega Funds where she served as the board director or observer for Scorpion Therapeutics, Arrakis Therapeutics, IFM, and additionally led or co-led Omega's investments in Theseus (NASDAQ: THRX), Ikena (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, she began her career with Polaris Partners. She served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Lyra Therapeutics (NASDAQ: LYRA), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO. She completed her postdoctoral fellowship in Robert Langer's lab in the Chemical Engineering department at the Massachusetts Institute of Technology. During her time at MIT, she founded the MIT Postdoctoral Association and served as its President. She also served on the MIT Intellectual Property Committee. She completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine. She graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology and chemistry. She attended East Carolina University on a full athletic scholarship and served as the captain of the women's varsity tennis team. [Source: Public Company Filing]